Research location

Stockbridge

Georgia, United States

Published trials86

Site observations87

Linked trials published86

Page1 / 2

Research activity in Stockbridge

Georgia, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 86 trials and 87 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Stockbridge

86 linked trials · page 1 of 2

Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)NCT07711691 · 2026-09-16 · 1 site observation

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes MellitusNCT07776509 · 2026-08-24 · 1 site observation

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusNCT07784725 · 2026-08-19 · 1 site observation

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190 · 2026-02-10 · 1 site observation

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886 · 2026-02-06 · 1 site observation

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)NCT04852887 · 2021-06-23 · 1 site observation

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or ObesityNCT07575932 · 2026-05-11 · 1 site observation

ACTIVE_NOT_RECRUITING

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs AloneNCT06862791 · 2025-02-18 · 1 site observation

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)NCT06635824 · 2024-11-25 · 1 site observation

ACTIVE_NOT_RECRUITING

CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on InsulinNCT06601166 · 2024-08-15 · 1 site observation

ACTIVE_NOT_RECRUITING

Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)NCT06483945 · 2024-02-28 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminNCT06192108 · 2024-01-10 · 1 site observation

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminNCT06045221 · 2023-09-22 · 1 site observation

A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833NCT06019559 · 2023-09-15 · 1 site observation

A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneNCT05971940 · 2023-08-09 · 1 site observation

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421 · 2023-04-03 · 1 site observation

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382286 · 2022-07-25 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care SettingNCT05348733 · 2022-06-13 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast CancerNCT04539938 · 2020-12-01 · 1 site observation

Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ PlatformNCT04100811 · 2019-12-01 · 1 site observation

House Dust Mite Allergy Trial In ChildrenNCT04145219 · 2019-10-12 · 1 site observation

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerNCT03199885 · 2019-04-05 · 1 site observation

GB001 in Adult Subjects With Moderate to Severe AsthmaNCT03683576 · 2018-10-22 · 1 site observation

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic TrialNCT03596450 · 2018-07-13 · 1 site observation

Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive DisorderNCT03569475 · 2018-07-06 · 1 site observation

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast CancerNCT03414970 · 2018-03-12 · 1 site observation

ACTIVE_NOT_RECRUITING

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant AsthmaNCT03358147 · 2017-12-13 · 1 site observation

Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled AsthmaNCT03347279 · 2017-11-23 · 1 site observation

Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb PainNCT03228420 · 2017-07-20 · 1 site observation

Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid ArthritisNCT02919761 · 2016-11-07 · 1 site observation

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe AsthmaNCT02918019 · 2016-09-20 · 1 site observation

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor AgonistNCT02738151 · 2016-05-19 · 1 site observation

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes MellitusNCT02688933 · 2016-05-05 · 1 site observation

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)NCT02727660 · 2016-04-29 · 1 site observation

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)NCT02642159 · 2016-03-15 · 1 site observation

Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)NCT02580591 · 2015-12-22 · 1 site observation

Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive DisorderNCT02431806 · 2015-06-23 · 1 site observation

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)NCT02451137 · 2015-06-16 · 1 site observation

A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid ArthritisNCT02287922 · 2015-03-01 · 1 site observation

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin GlargineNCT02294474 · 2015-01-01 · 1 site observation

A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid ArthritisNCT02309359 · 2015-01-01 · 1 site observation

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and HypertensionNCT02182830 · 2014-07-25 · 1 site observation

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary DiseaseNCT02157935 · 2014-06-27 · 2 site observations

A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μgNCT02091986 · 2014-04-01 · 1 site observation

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic NephropathyNCT02065791 · 2014-02-17 · 1 site observation

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.NCT01966107 · 2013-10-16 · 1 site observation

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic TherapyNCT01676220 · 2012-08-01 · 1 site observation

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes MellitusNCT01627340 · 2012-07-24 · 1 site observation

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)NCT01601704 · 2012-06-01 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.